Development of resistance to daunomycin (NSC-82151) in Ehrlich ascites tumor.
D000818:Animals; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy*; D003561:Cytarabine / Q000494:pharmacology; D003630:Daunorubicin / Q000008:administration & dosage / Q000494:pharmacology* / Q000633:toxicity; D004351:Drug Resistance; D005260:Female; D007274:Injections, Intraperitoneal; D008297:Male; D015122:Mercaptopurine / Q000494:pharmacology; D008727:Methotrexate / Q000494:pharmacology; D051379:Mice; D009368:Neoplasm Transplantation; D009607:Nitrosourea Compounds / Q000627:therapeutic use; D013997:Time Factors; D014750:Vincristine / Q000494:pharmacology
D009607:Nitrosourea Compounds; D003561:Cytarabine; D014750:Vincristine; D015122:Mercaptopurine; D008727:Methotrexate; D003630:Daunorubicin